Hormone Therapy for Prostate Cancer Salisbury MD

Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

John Henry Shenasky II, MD
(410) 546-2133
5396 Nithsdale Dr
Salisbury, MD
Specialties
Urology
Gender
Male
Education
Medical School: Cornell Univ Med Coll, New York Ny 10021
Graduation Year: 1967

Data Provided by:
Harold Iles Genvert, MD
(410) 546-2133
1342 S Division St Ste 401
Salisbury, MD
Specialties
Urology
Gender
Male
Education
Medical School: Cornell Univ Med Coll, New York Ny 10021
Graduation Year: 1981

Data Provided by:
Christopher Doyle Maull, MD
(410) 546-2133
1342 S Division St Ste 401
Salisbury, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Tn, Memphis, Coll Of Med, Memphis Tn 38163
Graduation Year: 1994

Data Provided by:
Luis Jose Barriocanal, MD
(302) 629-4528
220 Pennsylvania Ave
Seaford, DE
Specialties
Urology
Gender
Male
Education
Medical School: Univ Nac De Asuncion, Fac De Cien Med, Asuncion, Paraguay
Graduation Year: 1966
Hospital
Hospital: Nanticoke Mem Hosp, Seaford, De

Data Provided by:
Dr.Thomas B. Benz
(302) 628-4222
9096 Riverside Drive
Seaford, DE
Gender
M
Education
Medical School: Univ Of Pittsburgh Sch Of Med
Year of Graduation: 1982
Speciality
Urologist
General Information
Hospital: Nanticoke Mem Hosp, Seaford, De
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 2, reviews.

Data Provided by:
Mark Thomas Edney, MD
(410) 546-2133
1342 S Division St Ste 401
Salisbury, MD
Specialties
Urology
Gender
Male
Education
Medical School: Dartmouth Med, Hanover Nh 03755
Graduation Year: 1998

Data Provided by:
Thomas Michael De Marco, MD
(410) 546-2133
1342 S Division St Ste 401
Salisbury, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Louisville Sch Of Med, Louisville Ky 40202
Graduation Year: 1977

Data Provided by:
Thomas B Benz
(302) 628-4222
9096 Riverside Dr
Seaford, DE
Specialty
Urology

Data Provided by:
Jose L Barriocanal
(302) 629-4528
220 Pennsylvania Ave
Seaford, DE
Specialty
Urology

Data Provided by:
Thomas Bartley Benz, MD
(302) 628-4422
105 N Front St Apt A
Seaford, DE
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Pittsburgh Sch Of Med, Pittsburgh Pa 15261
Graduation Year: 1982
Hospital
Hospital: Nanticoke Mem Hosp, Seaford, De
Group Practice: Benz Urology

Data Provided by:
Data Provided by:

Hormone Therapy for Prostate Cancer

Provided By:

TUESDAY, Sept. 22 (HealthDay News) -- Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found.

The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

The study findings were scheduled to be presented Tuesday at the European Cancer Organization meeting in Berlin.

In a news release from the European Cancer Organization, the researchers described the types of hormone therapy used: removal of the testicles to eliminate the main source of testosterone production; injections of gonadotropin-releasing hormone agonists to reduce testosterone production by the testicles; and anti-androgen pills that block testosterone from attaching to prostate cells. Most of the patients received one treatment, but 38 percent were given two types of drugs, the study authors noted.

The men were followed for an average of three years and monitored for ischemic heart disease, heart attacks, arrhythmia, and heart failure.

"We found that prostate cancer patients treated with hormone therapy had an elevated risk of developing all of the individual types of heart problems and that they were more likely than normal to die from those causes," study lead author Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London, England, said in the news release.

Specifically, hormone therapy was associated with a 24 percent increased risk of heart attack, a 19 percent increased risk of arrhythmia, a 31 percent increased risk of ischemic heart disease, and a 26 percent increased risk of heart failure, the researchers found. The increased risk of heart disease began a few months after the men began hormone therapy.

The study also found that hormone therapy was associated with a 28 percent increased risk of fatal heart attack, a 21 percent increased risk of dying from heart disease, a 26 percent increased risk of death from heart failure, and a 5 percent increased risk of fatal arrhythmia.

"In a more detailed analysis by type of hormone therapy, the lowest increase in risk for ischemic heart disease, heart attack and heart failure was seen in the group taking anti-androgen therapy, and we saw no increase in risk of death from heart disease in this group. Patients on gonadotropin-releasing hormone agonist therapy had the highest risk of these problems," Van Hemelrijck said.

The findings suggest that physicians should consider heart-related side effects when prescribing hormone therapy for prostate cancer patients and may want to refer patients to a cardiologist before the start of hormone therapy, the researchers stated.

More information

The American Urological Association Foundation has more about hormone therapy for prostate cancer.

SOURCE: European Cancer Organization, news release, Sept. 22, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com